A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
M.D. Anderson Cancer Center
Takeda
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
Novartis
M.D. Anderson Cancer Center
Thomas Jefferson University
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
PharmaEssentia Japan K.K.
Novartis
Novartis
Incyte Corporation
Masonic Cancer Center, University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID)
M.D. Anderson Cancer Center
Protagonist Therapeutics, Inc.
Center for International Blood and Marrow Transplant Research
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Olavs Hospital
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Groupe Francophone des Myelodysplasies
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Blueprint Medicines Corporation
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Novartis
University of Campinas, Brazil
Aprea Therapeutics
University of Liverpool
Fred Hutchinson Cancer Center
City of Hope Medical Center
Ascentage Pharma Group Inc.
Icahn School of Medicine at Mount Sinai